U.S. Hummus Market Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032: Mediterranean Cuisine & Rising Popularity Propels Expansion, Sabra and Tribe Innovate with Bold Flavors
The U.S. hummus market is set to grow from $1.08 billion in 2025 to $1.86 billion by 2032, at an 8.0% CAGR. Driven by rising demand for healthy, plant-based snacks, major brands like Sabra and Tribe offer innovative flavors and on-the-go solutions. The surge in Mediterranean cuisine boosts this trend.
Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "U.S. Hummus Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Country: (U.S.)" has been added to ResearchAndMarkets.com's offering.
The market is anticipated to climb from a value of US$ 1.08 billion in 2025 to US$ 1.86 billion by 2032, with a steady CAGR of 8.0% forecasted between 2025 and 2032.
The U.S. hummus market is on a promising upward trend, fueled by a rising demand for plant-based, health-focused, and convenient food options. Increasing consumer attention toward ethical sourcing, functional ingredients, and international culinary influences has transformed hummus from a niche ethnic dip into a mainstream staple.
Market Insights
Hummus has gained significant popularity among U.S. consumers, particularly millennials, due to its versatility, nutritional benefits, and compatibility with various dietary preferences, including vegan and vegetarian lifestyles. Widely used as a dip, spread, or meal component, hummus is a nutritious alternative to traditional snacks, enriched with protein, fiber, and essential nutrients.
Prominent brands like Sabra and Tribe are tapping into this growth by offering diverse flavors, from classic garlic to bold innovations like cocoa and dessert-style hummus. The appetite for adventurous flavors and convenient snack solutions continues to drive market growth.
Market Drivers
The U.S. hummus market is spurred by an expanding consumer base seeking healthier snack options, consciously avoiding processed and calorie-laden products. With its high protein content, clean-label advantages, and plant-based recipe, hummus is ideally positioned. The surge in vegan and vegetarian dietary patterns complements the rising demand for such dips.
Also propelling market growth is the burgeoning appreciation for Mediterranean cuisine in the U.S. Culinary exploration, especially among younger demographics, has spotlighted hummus as a go-to choice for globally inspired foods. Dining venues and meal kits featuring hummus are further embedding it into regular consumption habits.
Business Opportunity
The market offers substantial opportunities for innovation in product diversification and packaging. Companies are launching single-serve, portion-controlled packs that meet increasing convenience demands, appealing to fitness enthusiasts and on-the-go professionals.
There's also a trend towards functional hummus products, enriched with superfoods and nutrients like turmeric and kale, targeting health-conscious consumers seeking additional nutritional benefits.
Brands are aligning with the clean-label movement, emphasizing ingredient transparency and utilizing organic and non-GMO ingredients, resonating with consumers prioritizing health, sustainability, and authenticity.
Regional Analysis
The U.S. hummus market is experiencing balanced growth across major regions, including the West, Midwest, Southwest, Southeast, and Northeast. The West and Northeast U.S. regions remain strongholds due to higher consumer awareness and a health-conscious populous. Emerging markets in the South and Midwest are seeing new opportunities as distribution channels increase and consumer preferences evolve.
Key Players
The market features a blend of established players and dynamic startups. Companies like Lakeview Farms, LLC, Hope Foods, LLC, Nestle S.A., Strauss Group, Cedar's Mediterranean Foods, Inc., and Lantana Foods are pivotal in shaping market trends. These companies are heavily investing in R&D to develop unique flavors, functional products, and sustainable packaging.
Major corporations like Nestle are expanding their reach through strategic partnerships with retail giants, while smaller brands focus on premium ingredients and distinctive flavors targeting niche consumer segments.
Challenges in the Market
Despite optimistic growth, the hummus market faces competition from other plant-based dips and spreads. Consumers are increasingly exploring alternatives like guacamole, nut-based dips, and black bean spreads, necessitating continuous innovation in flavor and function, alongside a commitment to transparency and sustainability.
Conclusion
Driven by health consciousness, plant-based diet trends, and global culinary inspiration, the U.S. hummus market is poised for significant growth. With an 8.0% projected CAGR from 2025 to 2032, the industry offers robust prospects for innovation, expansion, and consumer engagement.
Key Topics Covered:
Executive Summary
U.S. Hummus Market Snapshot
Future Projections
Key Market Trends
Regional Snapshot, by Value, 2025
Analyst Recommendations
Market Overview
Market Definitions and Segmentations
Market Dynamics
Drivers
Restraints
Market Opportunities
Value Chain Analysis
Porter's Five Forces Analysis
COVID-19 Impact Analysis
Impact Of Ukraine-Russia Conflict
Economic Overview
World Economic Projections
Pestle Analysis
U.S. Hummus Market Outlook, 2019-2032
U.S. Hummus Market Outlook, by Type, Value (US$ Mn) 2019-2032
U.S. Hummus Market Outlook, by Nature, Value (US$ Mn) 2019-2032
U.S. Hummus Market Outlook, by Sales Channel, Value (US$ Mn) 2019-2032
Competitive Landscape
Company Market Share Analysis, 2025
Competitive Dashboard
Company Profiles
Cedar's Mediterranean Foods, Inc.
Haliburton International Foods, Inc.
Hope Foods, LLC
Strauss Group
Boar's Head Brand
Zacca Hummus
Lakeview Farms, LLC
Nestle S.A.
Lantana Foods
Bakkavor Group Plc
For more information about this report visit https://www.researchandmarkets.com/r/7jb0t1
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment
Discover the future of the Molecular Diagnostics - Infectious Disease sector with our comprehensive report. Explore how multiplex assays and rapid testing are transforming diagnosis and treatment amidst the boom in biotechnology and genomics. This detailed analysis covers dynamic trends such as pathogen evolution, globalization, and climate change impacts. Benefit from extensive insights, including U.S. Medicare Fee Schedules, and detailed global data. Equip your organization with expert knowledge today. Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2025-2029: Strategies, Trends, and Forecasts by Application, Place and Country with Market Analysis & Executive Guides" report has been added to offering. The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report - and find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever. The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing along with the most frequently used and billed tests. The report includes detailed breakouts for 15 countries and 4 regions. A detailed breakout for any country in the world is available to purchasers of the report. This research makes you the expert in your organization. Assistance and additional specific data is provided without additional charges. All report data is available in Excel format on request. Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication. Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this report. A range of dynamic trends are pushing market growth and company valuations. Trends like: Multiplex testing Pathogen evolution and pandemics Biotechnology advances in genetics Climate change Globalization The rise of rapid testing Key Topics Covered: 1 Market Guides1.1 Situation Analysis2 Introduction and Market Definition2.1 Market Definition2.1.1 Market Size2.1.2 Currency2.1.3 Years2.2 Methodology2.2.1 Methodology2.2.2 Sources2.2.3 Authors2.3 Perspective: Healthcare Spending2.3.1 Global Healthcare Spending2.3.2 Spending on Healthcare and Pharmaceuticals2.3.3 Spending on Diagnostics2.3.4 Important Role of Insurance for Medical Services2.4 The Nature of the IVD Product2.4.1 Features Overview2.4.2 The Misunderstood Feature2.4.3 Regulation2.4.4 The Newest Feature2.4.5 The Oldest Feature2.4.6 All About Scope2.4.7 Why Turnaround is Becoming More Important2.4.8 The Role of Trust2.5 The IVD Product of the Future3 Infectious Diseases - Guide to the Pathogens3.1 Infectious Disease Pathogens - The Big Picture3.1.1 Viruses3.1.2 Bacteria3.1.3 Fungi3.1.4 Parasites3.1.5 Prions3.1.6 Virulence3.1.7 Transmission3.2 The Coronavirus3.2.1 Severe acute respiratory syndrome (SARS)3.2.2 Middle East respiratory syndrome (MERS)3.2.3 COVID-19. The SARS CoV 2 Virus3.2.3.1 Signs and symptoms3.2.3.2 Transmission3.2.3.3 Diagnosis3.2.3.4 Prevention3.2.3.5 Management3.2.3.6 Prognosis4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 The Clinical Laboratory Market Segments4.2.1 Traditional Market Segmentation4.2.2 Laboratory Focus and Segmentation4.2.3 Segmenting the Syndromic Testing Market4.3 Industry Structure4.3.1 Hospital Testing Share4.3.2 Economies of Scale4.3.3 Hospital vs. Central Lab4.3.4 Physician Office Lab's4.3.5 Physician's and POCT5 Market Trends5.1 Factors Driving Growth5.1.1 The Nucleic Acid Impact5.1.2 Population Dynamics5.1.3 The Developing World5.1.4 Decentralization5.1.5 Self Testing5.1.6 The Need for Speed5.2 Factors Limiting Growth5.2.1 Costs and Experience Curve Effects5.2.2 The Role of ID Prevalence5.2.3 Wellness5.2.4 The Impact of Living Standards5.3 Instrumentation, Automation and Diagnostic Trends5.3.1 Traditional Automation and Centralization5.3.2 The New Automation, Decentralization and Point of Care5.3.3 Instruments Key to Market Share5.3.4 Bioinformatics Plays a Role5.3.5 PCR Takes Command5.3.6 Next Generation Sequencing Fuels a Revolution5.3.7 NGS Impact on Pricing5.3.8 Whole Genome Sequencing, A Brave New World5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment6 Clinical Laboratory MDx Infectious Disease Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Presymptom Health Nabs Funding for Sepsis Test6.3 FDA Clears BioMerieux GI Panel6.4 Rapid Infection Diagnostic Launches BSIDx6.5 Biotia's AI-, Sequencing-Based UTI Test approved6.6 Delve Bio, Broad Clinical Labs Partner for Metagenomic6.7 Roche Respiratory Panel Receives FDA EUA6.8 Genetic Signatures Gets Approval for GI Parasite Panel6.9 Diasorin Expands Respiratory Panel6.10 BioMerieux Outlines MDx-Driven Growth6.11 T2 Biosystems Gets Extended T2Bacteria Panel6.12 Diasorin Aims to Deliver Updated Instruments, New Assays6.13 Oxford Nanopore Nabs Investment From BioMerieux6.14 Day Zero Diagnostics Closes Financing Round6.15 Spindiag Seeks Investors for Rapid PCR System6.16 Sorrento Therapeutics Nabs Contract for Dx Platform6.17 Kephera Planning Menu of Infectious Disease Tests6.18 Oxford Nanopore and BioMerieux to Develop IDDx6.19 SD Biosensor Eyes Global Expansion6.20 Selux Dx Next Gen Phenotyping Gets FDA Clearance6.21 Takara Developing High-Throughput Multiplex Panels6.22 BioGX Debuts New Point-of-Care Molecular Testing System6.23 Nanopath MDx Platform Providing 15-Minute Results6.24 ProtonDx Commercializing Rapid MDx Instrument6.25 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays6.26 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS6.27 Accelerate Diagnostics Anticipates Growth6.28 Lumos Diagnostics Expanding Test Portfolio6.29 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens7 Key Companies7.1 Abbott Laboratories7.2 Agilent7.3 Altona Diagnostics7.4 Anitoa7.5 Autonomous Medical Devices7.6 Beckman Coulter Diagnostics (Danaher)7.7 Becton, Dickinson and Company7.8 BioGX7.9 Biomatik7.10 bioMerieux Diagnostics7.11 Bio-Rad Laboratories, Inc.7.12 Cepheid (Danaher)7.13 Diasorin S.p.A.7.14 DNAe7.15 Flow Health7.16 Global Access Diagnostics7.17 Great Basin Scientific, Inc.7.18 Hologic7.19 Novacyt7.20 Novus Diagnostics7.21 Oncimmune7.22 One Codex7.23 OraSure Technologies7.24 Prometheus Laboratories7.25 Qiagen7.26 QuidelOrtho7.27 R-Biopharm AG7.28 Response Biomedical7.29 Revvity7.30 Roche Diagnostics7.31 Siemens Healthineers7.32 Thermo Fisher Scientific7.33 Vela Diagnostics7.34 Veredus Laboratories7.35 YD Diagnostics7.36 Zhejiang Orient Gene Biotech8 The Global Market for Clinical Laboratory MDx Infectious Disease8.1 Global Market Overview by Country8.2 Global Market by Application - Overview8.3 Global Market by Place - Overview9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application9.1 Respiratory9.2 Blood Borne Virus9.3 Transplant9.4 Hospital Acquired Infections9.5 Reproductive Health9.6 C19 Singleplex9.7 Meningitis9.8 Gastrointestinal9.9 Tropical10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place10.1 Hospital Lab10.2 Outpatient Lab10.3 Point of Care10.4 Other Place11 Appendices11.1 Growth of Approved IVD Test Menu11.2 Growth of Approved Average IVD Test Fee11.3 The Most Used IVD Assays11.4 The Highest Grossing Assays11.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
36 minutes ago
- Yahoo
2025 Aromatherapy and Essential Oils Market Analysis Report: Holistic-Well-Being, Transparency, Sustainable Practices, Certifications and Claims, and AI-Powered Personalized Scents
The Global Aromatherapy and Essential Oils Market is poised for substantial growth, with a forecasted CAGR over 6%, driven by heightened well-being awareness and social media influence. Valued at over $8 billion in 2024, North America leads with 45% market share, fueled by holistic wellness trends. Asia-Pacific follows closely, propelled by demographic changes and Gen Z's health focus. Companies prioritizing personalized, natural solutions will thrive. The comprehensive report includes market size, revenue forecasts, trends, and more. Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "2025 Aromatherapy and Essential Oils Market" report has been added to offering. The Global Aromatherapy and Essential Oils Market is set for consistent growth, with a projected CAGR exceeding 6% during 2024-2031 This expansion is driven by a growing emphasis on well-being, the rise of the she economy, the influence of social media, direct selling model and the increasing adoption of complementary and alternative medicine. The global market was valued over $8 billion in 2024. North America made up the largest portion of the global market with over 45% in revenues in 2024, followed by Asia Pacific with over 40% of revenues. The North American market is being driven by growing consumer interest in holistic wellness and natural remedies. As people become more focused on mental and emotional health, essential oils are being used for anxiety relief, stress management, and mindfulness. The rising awareness of sleep hygiene has also fueled demand for essential oil blends that promote relaxation and better sleep. Wellness brands are responding by offering more specialized products. The Asia-Pacific region is witnessing significant demographic and lifestyle shifts that are reshaping the wellness industry. Two primary factors driving this transformation are the aging population and the growing health-consciousness of younger generations like Gen Z. These changes are boosting the demand for products and services focusing on overall well-being. As European consumers continue to prioritize personalized and natural wellness solutions, the aromatherapy and essential oils market is poised for sustained growth. Companies that align their product lines with specific consumer needs, while emphasizing safety, sustainability, and quality, will remain competitive in this evolving landscape. Report Scope A comprehensive analysis of the Global Aromatherapy and Essential Oils Market for North America, Latin America, Europe, Asia-Pacific, and Rest of World, which includes market sizing, market share by competitor, drivers, restraints, regional trends and revenue forecasts to 2031. Essential oils are defined as natural oils, typically obtained by distillation, having the characteristic fragrance from the plant or other source extraction. Technically, aromatherapy means the use of aromas as therapy or the use of aromas for their healing properties. However, there is an increasing move to use the term 'essential oils' (which more accurately describes the existing market) as the therapeutic use of essential oils based on their aroma and properties, which includes internal use of the oils. For purposes of this research, only essential oils that are used for health and wellness and relaxation purposes via topical application, inhalation, diffusion, and ingestion have been included. The report includes the following information: Market Size, Growth Rate, Revenue Forecast (2024-2031) Revenue Share by Segment (distribution channel, product type, customer segment) Growth Drivers & Restraints Competitive Factors Industry Challenges Market Trends Regional Trends Pricing Trends Distribution Trends Regulatory Information Major Company Profiles Every report purchase comes with 1 hour of Analyst Inquiry Time for a phone call with the analysts. This can be used for strategic advice, consultation, or addressing issues in your business and linking them to a solution. Analyst Inquiry Time must be used within 45 days of report purchase. Key Topics Covered: 1. Research Scope, Methodology, Definition 2. Executive Summary Major Data Points - Global Revenue by Region, 2024 Revenue, Global, 2019-2024 3. Competitive Factors 4. Consumer Behavior 5. Market Drivers and Impact 6. Market Restraints and Impact 7. Global Trends Holistic-Well-Being Transparency Sustainable Practices Certifications and Claims AI-Powered Personalized Scents 8. Market Data - Global Total Market Revenue and Forecast Market Share by Company Distribution Share Analysis Market Share by Product Type 9. Competitive Landscape dOTERRA International, LLC Young Living Essential Oils, LC Melaleuca, Inc. 10. North America Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Market Data 11. Asia-Pacific Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Major Markets - China, South Korea, Japan, and Australia Market Data 12. Europe Major Data Points Consumer Behavior Market Drivers and Impact Market Restraints and Impact Market Trends Major Markets - Germany, and United Kingdom Market Data 13. Latin America Major Data Point Consumer Behavior Market Drivers and Impact Market Restrains and Impact Market Trends Market Data 14. Market Data - Rest of the World Companies Featured doTERRA Young Living Melaleuca Inc. Ryohin Keikaku Co. Ltd. Plant Therapy Neal's Yard Remedies Jurlique Saje Natural Business Inc. Frontier Co-op (Aura Cacia) Rocky Mountain Oils Eden Botanicals Melaleuca Plant Therapy rareEssence Eden Gardens Essential oils Nature Packaged Swiss Just America Exotic Aroma Perfect Potion Essentials Quintis @aroma Primavera Life GmbH First Natural Brands (Tisserand) Farfalla Terra Gaia Florihana Neom well-being Aromatherapy Associates Absolute Aromas For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Yahoo
an hour ago
- Yahoo
QuantaSing Announces Unaudited Financial Results for the Third Quarter of Fiscal Year 2025
BEIJING, June 06, 2025 (GLOBE NEWSWIRE) -- QuantaSing Group Limited (NASDAQ: QSG) ('QuantaSing' or the 'Company'), a leading lifestyle solution provider, today announced its unaudited financial results for the third quarter of the fiscal year ending June 30, 2025 (the 'third quarter of FY 2025', which refers to the quarter from January 1, 2025 to March 31, 2025). Business and Financial Highlights for the Third Quarter of FY 2025 Revenues for the third quarter of FY 2025 were RMB570.7 million (US$78.6 million), representing a decrease of 21.5% from the second quarter of the fiscal year ending June 30, 2025 (the 'second quarter of FY 2025') and a decrease of 39.6% from the third quarter of the fiscal year ended June 30, 2024 (the 'third quarter of FY 2024'). Gross billings of individual online learning services1 for the third quarter of FY 2025 were RMB515.6 million (US$71.0 million), representing a decrease of 5.6% from the second quarter of FY 2025 and a decrease of 47.5% from the third quarter of FY 2024. Net income for the third quarter of FY 2025 was RMB41.1 million (US$5.7 million), representing a decrease of 67.5% from the second quarter of FY 2025 and an increase of 181.2% from the third quarter of FY 2024. Adjusted net income2 for the third quarter of FY 2025 was RMB37.8 million (US$5.2 million), representing a decrease of 71.3% from the second quarter of FY 2025 and an increase of 18.5% from the third quarter of FY 2024. Total registered users increased by 19.9% to approximately 145.0 million as of March 31, 2025, from 121.0 million as of March 31, 2024. Paying learners was approximately 0.3 million in the third quarter of FY 2025. Company Highlight for the Third Quarter of FY 2025 Completed acquisition of 61% equity interest in Shenzhen Yiqi Culture Co., Ltd. ("Letsvan") on March 31, 2025 for a total cash consideration of RMB235.0 million through a multi-step transaction. Results of operations of Letsvan were included in consolidated financials of the Company beginning April 1, 2025. The acquired assets and liabilities of Letsvan are included at fair value in the Company's consolidated balance sheet as of March 31, 2025. Mr. Peng Li, Chairman and Chief Executive Officer of QuantaSing, commented, 'Our third quarter results reflect our strategic pivot toward product-driven business models that create long-term value. The acquisition of Letsvan marks a significant milestone in our expansion into the pop toys market, a sector with strong growth potential that perfectly aligns with our brand-first philosophy. The early success of our WAKUKU IP, including the recent Fox and Rabbit collection launch, validates our approach of pairing strong product development capabilities with efficient go-to-market strategies. As we integrate Letsvan's operations, we're applying our test-and-scale methodology to build a global presence in this resilient market segment. We aim to create businesses where brand strength and product excellence drive sustainable growth, rather than simply pursuing traffic-driven metrics.' Mr. Dong Xie, Chief Financial Officer of QuantaSing, added, 'Our financial performance this quarter underscores our commitment to disciplined capital allocation during this transformation phase. While revenue moderated to RMB570.7 million as we shifted resources away from traffic-driven businesses, we've maintained strong cash generation across our businesses. Our ROI-focused assessment methodology has allowed us to exit underperforming areas while preserving resources for high-potential opportunities. With our healthy cash position, we have the flexibility to support both our existing operations and our strategic initiatives in the pop toys space. Though we anticipate some near-term profitability fluctuations as we optimize our business mix, our financial foundation remains robust as we execute this strategic evolution.' Financial Results for the Third Quarter of FY 2025 Revenues Revenues were RMB570.7 million (US$78.6 million) in the third quarter of FY 2025, compared to RMB945.6 million in the third quarter of FY 2024. The change reflects the Company's deliberate shift from traffic-driven growth to high-quality growth. Revenues from individual online learning services decreased by 43.6% year over year to RMB467.2 million (US$64.4 million) in the third quarter of FY 2025, from RMB828.1 million in the third quarter of FY 2024. This decrease was primarily due to a decrease of RMB268.3 million (US$37.0 million) in revenues from skills upgrading courses, a decline of RMB74.1 million (US$10.2 million) in revenues from financial literacy courses and a decline of RMB18.5 million (US$2.5 million) in revenues from recreation and leisure courses. Revenues from enterprise services were RMB48.1 million (US$6.6 million) in the third quarter of FY 2025, compared to RMB65.1 million in the third quarter of FY 2024, representing a year-over-year change of 26.1%. The decline was primarily driven by reduced marketing services to enterprise customers. Revenues from consumer business3 were RMB48.7 million (US$6.7 million) in the third quarter of FY 2025, compared to RMB49.4 million in the third quarter of FY 2024. The slight change was primarily attributable to the decline in baijiu revenue, partially offset by the modest increase in wellness products revenue. Revenues from others3 were RMB6.7 million (US$0.9 million) in the third quarter of FY 2025, compared to RMB3.0 million in the third quarter of FY 2024, primarily due to revenue from the Company's newly initiated business. Cost of revenues Cost of revenues was RMB96.6 million (US$13.3 million) in the third quarter of FY 2025, compared to RMB145.8 million in the third quarter of FY 2024, representing a 33.8% decrease. The decrease was primarily due to reduced labor outsourcing costs of RMB22.1 million (US$3.1 million), decreased procurement costs of RMB9.6 million (US$1.3 million) and lower staff costs of RMB5.1 million (US$0.7 million). Sales and marketing expenses Sales and marketing expenses were RMB395.2 million (US$54.5 million) in the third quarter of FY 2025, compared to RMB729.6 million in the third quarter of FY 2024, representing a decrease of 45.8%. The decrease was mainly due to a reduction in marketing and promotion expenses of RMB265.1 million (US$36.5 million), labor outsourcing costs of RMB46.4 million (US$6.4 million), and staff costs of RMB7.9 million (US$1.1 million), which included a decrease in share-based compensation expenses of RMB2.1 million (US$0.3 million). Research and development expenses Research and development expenses were RMB20.9 million (US$2.9 million) in the third quarter of FY 2025, compared to RMB38.8 million in the third quarter of FY 2024, representing a decrease of 46.2%. The decrease was primarily due to lower staff costs of RMB16.0 million (US$2.2 million). General and administrative expenses General and administrative expenses were RMB25.0 million (US$3.5 million) in the third quarter of FY 2025, compared to RMB36.4 million in the third quarter of FY 2024, representing a decrease of 31.2%. The decrease was primarily due to lower staff costs of RMB8.0 million (US$1.1 million), which included a decrease in share-based compensation expenses of RMB5.5 million (US$0.8 million). Remeasurement gain of previously held equity interests in connection with step acquisitions Remeasurement gain of previously held equity interests in connection with step acquisitions were RMB8.1 million (US$1.1 million) in the third quarter of FY 2025, reflecting the fair value adjustment of initial investments in Letsvan before obtaining control. Details of the acquisition can be found in the Recent Developments section of this report. Others, net Others, net were RMB15.4 million (US$2.1 million) in the third quarter of FY 2025, compared to RMB7.7 million in the third quarter of FY 2024, primarily driven by the increased fair value gains in one of the Company's long-term investments. Net income and adjusted net income Net income was RMB41.1 million (US$5.7 million) in the third quarter of FY 2025, compared to RMB14.6 million in the third quarter of FY 2024. Adjusted net income was RMB37.8 million (US$5.2 million) in the third quarter of FY 2025, compared to RMB31.9 million in the third quarter of FY 2024. Earnings per share and adjusted earnings per share4 Basic and diluted net income per share were both RMB0.25 (US$0.03) in the third quarter of FY 2025, compared to basic and diluted net income per share of RMB0.09 in the third quarter of FY 2024. Basic and diluted adjusted net income per share were RMB0.23 (US$0.03), in the third quarter of FY 2025, compared to RMB0.19 in the third quarter of FY 2024. Balance Sheet As of March 31, 2025, the Company had cash and cash equivalents, restricted cash and short-term investments of RMB1,134.9 million (US$156.4 million), compared with RMB1,026.3 million as of June 30, 2024. Recent Developments Investments in Letsvan On March 24, 2025, the Company announced that it entered into definitive agreements to invest in Shenzhen Yiqi Culture Co., Ltd., a PRC-based company specializing in IP incubation, copyright commercialization, and the promotion and sales of pop toys. The transaction marks the Company's strategic entry into the pop toys market and broader consumer goods sector. Upon the completion of the investments in March 2025, Letsvan became a controlled subsidiary of the Company. Letsvan currently operates a number of established IPs, including "WAKUKU", "ZIYULI", "FUNII", "FIILA" and "PIDOL", with distribution channels spanning both online and offline platforms across China and Southeast Asian markets. Letsvan's current growth strategy encompasses three key areas: strengthening collaborations with major retail partners to enhance IP influence and expand sales, developing self-operated retail locations including a recently opened pop-up store at Chaoyang Joy City in Beijing, and building comprehensive online brand and sales capabilities. International expansion initiatives are underway. Letsvan has already established its footprints in certain Southeast Asian markets and has been exploring opportunities in other overseas markets including the United States. With respect to IPs, Letsvan continues to strengthen internal product incubation and operational capabilities, partner with third-party artists, and collaborate with established IPs to diversify its product portfolio. Recent product launches include the "WAKUKU Fox and Bunny Trick or Treat", which commenced offline distribution on May 17, 2025, followed by online channel availability on May 20, 2025. The Beijing Chaoyang Joy City pop-up store launch has generated favorable user response and increased product visibility in the market. 2024 Share Repurchase Program On June 11, 2024, the Company announced that the Board had approved a share repurchase program of up to US$20.0 million of the Company's Class A ordinary shares in the form of ADSs for a 12-month period beginning on June 11, 2024 and ending on June 10, 2025 (the '2024 Share Repurchase Program'). As of March 31, 2025, a total of 1.7 million ADSs had been repurchased for an aggregate consideration of US$3.6 million under the 2024 Share Repurchase Program. 2025 Share Repurchase Program On June 6, 2025, the Company announced that the Board had approved a new share repurchase program of up to US$20.0 million of the Company's Class A ordinary shares in the form of ADSs for a purchase period beginning from June 11, 2025 and ending on June 30, 2026 (the '2025 Share Repurchase Program'). Repurchases under the 2025 Share Repurchase Program may be made from time to time through open market transactions at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means. The repurchases will be subject to all applicable rules and regulations, including Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, as well as the Company's insider trading policy. The number of ADSs repurchased and the timing of repurchases will also depend on a number of factors, including, but not limited to, price, trading volume and general market conditions, along with the Company's working capital requirements, general business conditions and other factors. The Board will review the 2025 Share Repurchase Program periodically, and may authorize adjustment of its terms and size or suspend or discontinue the program. The Company plans to fund the repurchases from its existing cash balance. Conference Call Information The Company's management team will hold an earnings conference call at 07:00 A.M. Eastern Time on Friday, June 6, 2025 (07:00 P.M. Beijing Time on the same day) to discuss the financial results. Listeners may access the call by dialing the following numbers: International: 1-412-902-4272 United States Toll Free: 1-888-346-8982 Mainland China Toll Free: 4001-201203 Hong Kong Toll Free: 800-905945 Conference ID: QuantaSing Group Limited The replay will be accessible through June 13, 2025 by dialing the following numbers: International: 1-412-317-0088 United States Toll Free: 1-877-344-7529 Replay Access Code: 3611954 A live and archived webcast of the conference call will be available at the Company's investor relations website at Non-GAAP Financial Measures To supplement the Company's consolidated financial statements, which are prepared and presented in accordance with U.S. GAAP, the Company uses gross billings of individual online learning services, adjusted net income and basic and diluted adjusted net income per share as its non-GAAP financial measures. Gross billings of individual online learning services for a specific period represents revenues of the Company's individual online learning services net of the changes in deferred revenues in such period, further adjusted by value-added tax in such period. Adjusted net income represents net income excluding share-based compensation expenses and remeasurement gain of previously held equity interests inconnection with step acquisitions. Basic and diluted adjusted net income per share represents adjusted net income attributable to QuantaSing Group Limited divided by weighted average number of ordinary shares outstanding during the periods used in computing adjusted net income per share, basic and diluted. The Company believes that the non-GAAP financial measures provide useful information about the Company's results of operations, enhance the overall understanding of the Company's past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company's management in its financial and operational decision-making. The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools, and when assessing the Company's operating performance, investors should not consider them in isolation, or as a substitute for revenue, net income, net income per share, basic and diluted or other consolidated statements of operations data prepared in accordance with U.S. GAAP. The Company's definition of non-GAAP financial measures may differ from those of industry peers and may not be comparable with their non-GAAP financial measures. The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company's performance. For more information on these non-GAAP financial measures, please see the table captioned 'QuantaSing Group Limited Unaudited Reconciliation of GAAP and Non-GAAP Results' near the end of this release. Exchange Rate Information This announcement contains translations of certain Renminbi ('RMB') amounts into U.S. dollars ('US$') at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from Renminbi to U.S. dollars were made at the rate of RMB7.2567 to US$1.00, the exchange rate on March 31, 2025, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollars amounts referred to could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all. Safe Harbor Statements This announcement contains forward-looking statements within the meaning of Section 27A of Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended and the Private Securities Litigation Reform Act of 1955. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding QuantaSing's financial outlook, beliefs and expectations. These statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'potential,' 'continue,' 'ongoing,' 'targets,' 'guidance' and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the 'SEC'), in its annual report to shareholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's growth strategies; its future business development, results of operations and financial condition; its ability to attract and retain new users and learners and to increase the spending and revenues generated from users and learners; its ability to maintain and enhance the recognition and reputation of its brand; its expectations regarding demand for and market acceptance of its services and products; the expected growth, trends and competition in the markets that the Company operates in; changes in its revenues and certain cost or expense items; PRC governmental policies and regulations relating to the Company's business and industry, general economic and political conditions in China and globally, and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties, or factors is included in the Company's filings with the SEC, including, without limitation, the final prospectus related to the IPO filed with the SEC dated January 24, 2023. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. About QuantaSing Group Limited QuantaSing is a leading lifestyle solution provider that offers engaging, affordable and accessible online and offline services, as well as consumer products in selected areas that address senior users' wellness aspirations. QuantaSing has expanded into the pop toys sector and continues to strategically diversify its portfolio by capturing opportunities in promising consumer sectors while maintaining financial discipline. For more information, please visit: Contact Investor RelationsLeah GuoQuantaSing Group LimitedEmail: ir@ +86 (10) 6493-7857 Robin Yang, PartnerICR, LLCEmail: +1 (212) 537-0429 _________________________________1 Gross billings of individual online learning services is a non-GAAP financial measure. For a reconciliation of revenues of individual online learning services to gross billings of individual online learning services, see the 'Non-GAAP Financial Measures' section and the table captioned 'QuantaSing Group Limited Unaudited Reconciliation of GAAP and Non-GAAP Results' below.2 Adjusted net income is a non-GAAP financial measure. For a reconciliation of net income to adjusted net income, see the 'Non-GAAP Financial Measures' section and the table captioned 'QuantaSing Group Limited Unaudited Reconciliation of GAAP and Non-GAAP Results' below.3 Effective from the fourth quarter of FY 2024, the Company has introduced 'Revenues from Consumer Business' as a separate line item. This revenue was previously included in 'Revenues from Others'. The historical revenues presentation has been conformed to the current presentation.4 Basic and diluted adjusted net income per share are non-GAAP financial measures. For a reconciliation of basic and diluted net income per share to basic and diluted adjusted net income per share, see the 'Non-GAAP Financial Measures' section and the table captioned 'QuantaSing Group Limited Unaudited Reconciliation of GAAP and Non-GAAP Results' GROUP LIMITEDUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in thousands, except for share and per share data) As of June 30,2024 March 31,2025 March 31,2025 RMB RMB US$ ASSETS Current assets: Cash and cash equivalents 779,931 985,677 135,830 Restricted cash 160 675 93 Short-term investments 246,195 148,532 20,468 Accounts receivable, net 16,676 37,392 5,153 Amounts due from related parties 4,488 489 67 Inventory, net 6,345 28,120 3,875 Prepayments and other current assets 275,549 173,582 23,920 Total current assets 1,329,344 1,374,467 189,406 Non-current assets: Property and equipment, net 6,569 11,571 1,595 Long-term investments 9,010 44,428 6,122 Intangible assets, net - 68,973 9,505 Operating lease right-of-use assets 58,889 29,479 4,062 Deferred tax assets 847 914 126 Goodwill - 187,598 25,852 Other non-current assets 21,360 5,177 713 Total non-current assets 96,675 348,140 47,975 TOTAL ASSETS 1,426,019 1,722,607 237,381 LIABILITIES Current liabilities: Short-term Borrowings - 14,500 1,998 Accounts payables 62,066 55,219 7,609 Accrued expenses and other current liabilities 190,508 186,084 25,643 Income tax payable 20,399 53,565 7,381 Contract liabilities, current portion 385,227 310,189 42,745 Advance from customers 162,257 148,332 20,441 Operating lease liabilities, current portion 49,099 30,837 4,249 Total current liabilities 869,556 798,726 110,066 Non-current liabilities: Contract liabilities, non-current portion 11,365 33,495 4,616 Operating lease liabilities, non-current portion 16,989 3,123 430 Deferred tax liabilities 11,625 42,269 5,825 Total non-current liabilities 39,979 78,887 10,871 TOTAL LIABILITIES 909,535 877,613 120,937QUANTASING GROUP LIMITEDUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS- continued(Amounts in thousands, except for share and per share data) As of June 30,2024 March 31,2025 March 31,2025 RMB RMB US$ MEZZANINE EQUITY Non-controlling interests with liquidation preferences - 40,999 5,650 SHAREHOLDERS' EQUITY Class A ordinary shares 81 81 11 Class B ordinary shares 34 34 5 Treasury stock (109,257 ) (41,898 ) (5,774 ) Additional paid-in capital 1,192,474 1,069,620 147,398 Accumulated other comprehensive income 17,313 18,491 2,548 Accumulative deficit (584,161 ) (335,573 ) (46,243 ) TOTAL QUANTASING GROUP LIMITED SHAREHOLDERS' EQUITY 516,484 710,755 97,945 Non-controlling interests - 93,240 12,849 TOTAL SHAREHOLDERS' EQUITY 516,484 803,995 110,794 TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY 1,426,019 1,722,607 237,381QUANTASING GROUP LIMITEDUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME(Amounts in thousands, except for shares and per share data) For the Three MonthsEnded March 31, For the Nine MonthsEnded March 31, 2024 2025 2025 2024 2025 2025 RMB RMB US$ RMB RMB US$ Revenues 945,570 570,706 78,645 2,795,248 2,107,757 290,457 Cost of revenues (145,848 ) (96,556 ) (13,306 ) (409,058 ) (353,516 ) (48,716 ) Gross Profit 799,722 474,150 65,339 2,386,190 1,754,241 241,741 Operating expenses: Sales and marketing expenses (729,620 ) (395,175 ) (54,457 ) (2,006,884 ) (1,317,206 ) (181,516 ) Research and development expenses (38,840 ) (20,891 ) (2,879 ) (123,655 ) (77,325 ) (10,656 ) General and administrative expenses (36,390 ) (25,049 ) (3,452 ) (114,211 ) (86,194 ) (11,878 ) Total operating expenses (804,850 ) (441,115 ) (60,788 ) (2,244,750 ) (1,480,725 ) (204,050 ) (Loss)/Income from operations (5,128 ) 33,035 4,551 141,440 273,516 37,691 Other income: Interest income 2,513 880 121 8,369 4,040 557 Remeasurement gain of previously held equity interests in connection with step acquisitions - 8,109 1,117 - 8,109 1,117 Others, net 7,685 15,400 2,122 22,163 31,418 4,330 Income before income tax 5,070 57,424 7,911 171,972 317,083 43,695 Income tax benefit/(expense) 9,560 (16,280 ) (2,243 ) 16,948 (68,495 ) (9,439 ) Net income 14,630 41,144 5,668 188,920 248,588 34,256 Net loss attributable to noncontrolling interests - 1 - - 1 - Net income attributable to QuantaSing Group Limited 14,630 41,145 5,668 188,920 248,589 34,256 Other comprehensive income/(loss) Foreign currency translation adjustments, net of nil tax 423 (289 ) (40 ) (4,954 ) 1,178 162 Total other comprehensive income/(loss) 423 (289 ) (40 ) (4,954 ) 1,178 162 Total comprehensive income 15,053 40,855 5,628 183,966 249,766 34,418 Total comprehensive loss attributable to noncontrolling interests - 1 - - 1 - Comprehensive income attributable to QuantaSing Group Limited 15,053 40,856 5,628 183,966 249,767 34,418 Net income per ordinary share - Basic 0.09 0.25 0.03 1.14 1.55 0.21 - Diluted 0.09 0.25 0.03 1.10 1.52 0.21 Weighted average number of ordinary shares used in computing net income per share - Basic 164,753,256 162,791,862 162,791,862 166,399,349 160,479,027 160,479,027 - Diluted 170,890,581 165,216,173 165,216,173 171,089,530 163,949,787 163,949,787 Share-based compensation expenses included in Cost of revenues (2,878 ) (1,431 ) (197 ) (9,945 ) (5,214 ) (719 ) Sales and marketing expenses (2,779 ) (642 ) (88 ) 8,678 (1,540 ) (212 ) Research and development expenses (3,599 ) (167 ) (23 ) (10,611 ) (2,474 ) (341 ) General and administrative expenses (8,039 ) (2,571 ) (354 ) (28,961 ) (8,073 ) (1,112 ) QUANTASING GROUP LIMITEDUNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS(Amounts in thousands, except for shares and per share data) The following table below sets forth a reconciliation of revenues to gross billings for the periods indicated: For the Three MonthsEnded March 31, For the Nine MonthsEnded March 31, 2024 2025 2025 2024 2025 2025 RMB RMB US$ RMB RMB US$ Revenues of individual online learning services: 828,127 467,247 64,388 2,457,588 1,777,552 244,953 Add: value-added tax 52,986 27,919 3,847 147,665 101,969 14,052 Add: ending deferred revenues(1) 744,320 461,026 63,531 744,320 461,026 63,531 Less: beginning deferred revenues(1) (643,929 ) (440,632 ) (60,721 ) (661,360 ) (565,030 ) (77,863 ) Gross billings of individual online learning services 981,504 515,560 71,045 2,688,213 1,775,517 244,673 (1) Deferred revenues include contract liabilities, advance from customers, and refund liability of individual online learning services included in 'accrued expenses and other current liabilities'.QUANTASING GROUP LIMITEDUNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS - continued(Amounts in thousands, except for shares and per share data) The following table below sets forth a reconciliation of net income to adjusted net income and basic and diluted net income per share to basic and diluted adjusted net income per share for the periods indicated: For the Three MonthsEnded March 31, For Nine MonthsEnded March 31, 2024 2025 2025 2024 2025 2025 RMB RMB US$ RMB RMB US$ Net income 14,630 41,144 5,668 188,920 248,588 34,256 Add: Share-based compensation expenses 17,295 4,811 662 40,839 17,301 2,384 Less: Remeasurement gain of previously held equity interests in connection with step acquisitions - (8,109 ) (1,117 ) - (8,109 ) (1,117 ) Adjusted net income 31,925 37,846 5,213 229,759 257,780 35,523 Attributable to noncontrolling interests - 1 - - 1 - Adjusted net income attributable to QuantaSing Group Limited 31,925 37,847 5,213 229,759 257,781 35,523 Weighted average number of ordinary shares used in computing net income per share - Basic 164,753,256 162,791,862 162,791,862 166,399,349 160,479,027 160,479,027 - Diluted 170,890,581 165,216,173 165,216,173 171,089,530 163,949,787 163,949,787 Weighted average number of ordinary shares used in computing adjusted net income per share - Basic 164,753,256 162,791,862 162,791,862 166,399,349 160,479,027 160,479,027 - Diluted 170,890,581 165,216,173 165,216,173 171,089,530 163,949,787 163,949,787 Net income per ordinary share - Basic 0.09 0.25 0.03 1.14 1.55 0.21 - Diluted 0.09 0.25 0.03 1.10 1.52 0.21 Non-GAAP adjustments to net income per ordinary share - Basic 0.10 (0.02 ) 0.00 0.24 0.06 0.01 - Diluted 0.10 (0.02 ) 0.00 0.24 0.05 0.01 Adjusted net income per ordinary share - Basic 0.19 0.23 0.03 1.38 1.61 0.22 - Diluted 0.19 0.23 0.03 1.34 1.57 0.22Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data